Rifabutin and other derivatives of rifampin are inhibitory against Helicobacter pylori at very low concentrations in vitro (1, 4) . Triple therapy including rifabutin, amoxicillin, and a proton pump inhibitor has been effective in the eradication of H. pylori after failure of other therapies and in spite of resistance to other antibiotics (10) . Resistance to rifampin and rifabutin is caused by amino acid exchanges in the ␤ subunit of the DNA-directed RNA polymerase (RpoB). Mutations at codons 146, 507 to 533, 563 to 572, and 687 of the rpoB gene in Escherichia coli (11) or at codons 507 to 533 (cluster region) in Mycobacterium tuberculosis (8, 9) have been shown to induce resistance.
All resistant mutants of H. pylori ATCC 43504 selected in vitro in a previous investigation (4) showed mutations in the cluster region encompassing codons 525 to 545 and codon 586.
Here we describe a clinical isolate of H. pylori that developed resistance during therapy. The patient was treated with lanzoprazole and rifabutin, but amoxicillin was discontinued due to intolerance. Isolates of H. pylori before (DR62a) and after (DR62n) treatment were available for evaluation. Culture, storage, E-test, agar dilution assay, PCR, and sequencing of the cluster region were performed as described recently (4). Table 1 shows the primers for the amplification and evaluation of large and small segments of the respective rpoB regions.
Sequencing was performed in both directions (Perkin-Elmer Applied Biosystems).
DR62n was resistant to rifampin (E-test, MIC of Ͼ256 g/ ml) and rifabutin but, in contrast to previous findings (4), showed no difference from the published wild-type sequence (14) in the cluster region. The MICs of rifabutin for H. pylori DR62a and DR62n were 0.002 and 8 g/ml, respectively (Table 2). Both strains yielded homologous patterns when typed by arbitrarily primed PCR (2; unpublished work). Amplification and sequencing of DR62n rpoB (rifabutin resistant) from bp 387 to bp 916 revealed a codon exchange, GTC3TTC (V149F). DR62a (rifabutin susceptible) showed wild-type sequence in both the V149 region and the cluster region.
In order to confirm that the amino acid mutation V149F is responsible for high-level resistance, large fragments of the rpoB gene (bp 54 to 916 harboring codon 149 and bp 1271 to 2106 harboring the cluster region) from DR62n and DR62a were amplified and sequenced. The amino acid mutation V149F was the only difference between DR62n and DR62a or the published wild-type sequence (14) . All fragments were transformed into a competent, rifabutin-susceptible strain, H. pylori 2802A. Transformation of H. pylori 2802A was done, using a dense suspension of a fresh culture adjusted to a McFarland standard of Ͼ4 in 1 ml at an optical density value at 550 nm (OD 550 ) of 10, diluted to an OD 550 value of 0.2 in brucella broth with 8% fetal calf serum. One milliter of a suspension with an OD 550 value of 0.2 (in a 24-well plate) was incubated at 36°C with 3 to 5% CO 2 for 6 h. At 0, 2, and 4 h, 3 to 10 l of a PCR product (1 to 3 g of DNA) was added. Cells were cultured on Wilkins-Chalgren agar containing rifabutin (0.03 g/ml) under microaerophilic conditions for 3 to 5 days. Single colonies were picked and grown on selective agar for MIC determination, storage, DNA amplification, and sequencing. Repeated transformation of H. pylori 2802A with PCR products harboring the V149F mutation (bp 54 to 916 from DR62n rpoB) generated 10 5 to 10 6 CFU/well (2802A-R) showing the same level of resistance as seen in the donor strain (Table 2) . Transformation with PCR products of the wild-type 5Ј region (bp 54 to 916) or cluster region (bp 1371 to 2106) of H. pylori rpoB generated fewer than five resistant colonies per well.
Positive controls for the cluster region (e.g., Q527R) were amplified from the DNA of rifabutin-resistant H. pylori ATCC 43504 variants (4) and generated 10 5 to 10 6 CFU/well (data not shown).
After we had the confirmation of a newly described mutation outside the cluster region conferring high-level resistance in H. pylori, we wondered whether this arrangement might also occur in M. tuberculosis. PCR-based systems for the detection of mutations in the cluster region are of outstanding importance for the determination of rifampin susceptibility of slow-growing organisms like M. tuberculosis but sometimes fail to match with a resistant phenotype. Reported failure rates range from 3 to 6% (3, 5, 7, 9, 13, 16, 17) . DNA samples of six M. tuberculosis isolates from Japan for which MICs of rifampin were elevated but with wild-type sequence in the rpoB cluster region were provided by the authors of reference 17.
Primers for PCR and sequencing are shown in Table 1 . Three out of six samples showed the mutation GTC3TTC (V176F), consistent with our findings in DR62n. The amino acid changes detected are shown in Table 2 and mapped in Fig.  1 . There is no report in the literature so far of a mutation in this region in mycobacteria.
Rudi The amino acid mutation V146F conferring high-level resistance in E. coli was first observed by Lisitsyn et al. in 1984 (6) and verified by Severinov et al. (12) by site-directed mutagenesis (Fig. 1) . Recently, three mutations associated with resistance were described for a Rickettsia typhi isolate (15) . Mutations were observed at codons 151 (F151L), 201, and 271. Codon 151 is located next to the region which has been shown to confer resistance and is possibly the one responsible for the resistant phenotype. Out of six M. tuberculosis isolates, three with the higher level of resistance to rifampin (8 to 32 g/ml) carried the V176F mutation, while the low-level resistance (1 to 4 g/ml) remains unexplained.
Mutations in the 5Ј region of the rpoB gene inducing rifamycin resistance in H. pylori and possibly in M. tuberculosis have not been sufficiently examined. Resistance can be caused by a single base exchange outside the cluster region. This should be considered in future developments of molecular biology-based testing for mycobacteria.
The high homology of this region on the amino acid level (Fig. 1) 
